NEWS & EVENTS

Latest news and upcoming events

VarmX raises €30 million Series B2 financing for IND approval and preparations for pivotal trial
25 May 2023

VarmX raises €30 million Series B2 financing for IND approval and preparations for pivotal trial

Upcoming events

  • Biospain
    26 - 28 September 2023,
    Barcelona

    download

  • Bio€quity Europe
    14 - 16 May 2023,
    Dublin

    download

  • Swiss Biotech Day
    24 - 25 April 2023,
    Switzerland

    download
LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results<
11 Apr 2023

LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results

Initial clinical data for LAVA-051 suggest a favorable safety profile and initial anti-tumor activity in the ongoing dose escalation Phase 1/2a clinical trial
SparingVision appoints Joseph C. Papa as Chairman<
05 Apr 2023

SparingVision appoints Joseph C. Papa as Chairman

Former Bausch and Lomb Chairman and CEO joins as non-executive independent Chairman of SparingVision

Adcendo ApS Announces Extension of Series A Financing to 82M EUR to Ensure Broad Development of its First-in-class ADC Pipeline<
04 Apr 2023

Adcendo ApS Announces Extension of Series A Financing to 82M EUR to Ensure Broad Development of its First-in-class ADC Pipeline

Extension led by Pontifax Venture Capital and existing investors Novo Holdings and Ysios Capital, raising an additional 31M EUR
Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED<
27 Mar 2023

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

Now proceeding to Cohort 2 to evaluate the safety and efficacy of two doses of KPI-012

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update<
16 Mar 2023

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Lorundrostat pivotal clinical program, for the treatment of patients with uncontrolled hypertension, expected to begin in the first half of 2023

Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights<
15 Mar 2023

Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights

FDA Grants Fast Track Designation for Belzupacap Sarotalocan (bel-sar) for the Treatment of Choroidal Metastasis
Lava Therapeutics announces appointment of Christy J. Oliger to its board of directors<
10 Mar 2023

Lava Therapeutics announces appointment of Christy J. Oliger to its board of directors

Ms. Oliger brings extensive commercial, portfolio management, and senior leadership experience to the role
Am-Pharma to present data from phase 3 revival study at upcoming scientific conferences<
09 Mar 2023

Am-Pharma to present data from phase 3 revival study at upcoming scientific conferences

A significant reduction in major adverse kidney events by day 90 was observed

VarmX Appoints Dr. Jeffrey Lawson, MD, PhD as Chief Scientific Officer<
09 Mar 2023

VarmX Appoints Dr. Jeffrey Lawson, MD, PhD as Chief Scientific Officer

Dr. Lawson is a renowned scientist in blood coagulation biochemisty and surgical hemostasis.
Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC<
04 Mar 2023

Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC

Lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontrolled hypertension

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.